{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:09:45Z","timestamp":1792066185910,"version":"4.4.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministry of Health of the Czech Republic","doi-asserted-by":"publisher","award":["65269705"],"award-info":[{"award-number":["65269705"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013609","name":"EEA Grants\/Norway Grants","doi-asserted-by":"publisher","award":["EHP-BFNU-OVNKM-3-048-2020"],"award-info":[{"award-number":["EHP-BFNU-OVNKM-3-048-2020"]}],"id":[{"id":"10.13039\/501100013609","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["MUNI\/A\/1372\/2020"],"award-info":[{"award-number":["MUNI\/A\/1372\/2020"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["MUNI\/A\/1440\/2021"],"award-info":[{"award-number":["MUNI\/A\/1440\/2021"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Endocrinology & Metabolism"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.tem.2022.06.005","type":"journal-article","created":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T17:17:10Z","timestamp":1658769430000},"page":"628-638","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["GLP-1 agonists: superior for mind and body in antipsychotic-treated patients?"],"prefix":"10.1016","volume":"33","author":[{"given":"Katerina","family":"Horska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1846-0799","authenticated-orcid":false,"given":"Jana","family":"Ruda-Kucerova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silje","family":"Skrede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tem.2022.06.005_bb0005","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.3390\/nu12123883","article-title":"Exploring patterns of disturbed eating in psychosis: a scoping review","volume":"12","author":"Stogios","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.tem.2022.06.005_bb0010","first-page":"3111","article-title":"Cognitive dysfunction in bipolar disorder and schizophrenia: a systematic review of meta-analyses","volume":"11","author":"Bortolato","year":"2015","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.tem.2022.06.005_bb0015","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.tem.2022.06.005_bb0020","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/wps.20252","article-title":"Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis","volume":"14","author":"Vancampfort","year":"2015","journal-title":"World Psychiatry"},{"key":"10.1016\/j.tem.2022.06.005_bb0025","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1001\/jamapsychiatry.2021.0015","article-title":"Association between cardiovascular risk factors and cognitive impairment in people with schizophrenia: a systematic review and meta-analysis","volume":"78","author":"Hagi","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.tem.2022.06.005_bb0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055176","article-title":"Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden","volume":"8","author":"Nordentoft","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.tem.2022.06.005_bb0035","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1192\/bjp.bp.117.202606","article-title":"Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000\u20132014","volume":"211","author":"Hayes","year":"2017","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.tem.2022.06.005_bb0040","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41569-020-00463-7","article-title":"Cardiovascular disease in patients with severe mental illness","volume":"18","author":"Nielsen","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.tem.2022.06.005_bb0045","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2215-0366(17)30078-0","article-title":"Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis","volume":"4","author":"Hjorth\u00f8j","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.tem.2022.06.005_bb0050","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/acps.13017","article-title":"Undiagnosed cardiovascular disease prior to cardiovascular death in individuals with severe mental illness","volume":"139","author":"Heiberg","year":"2019","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.tem.2022.06.005_bb0055","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/PSY.0000000000001017","article-title":"Association of bipolar disorder with major adverse cardiovascular events: a population-based historical cohort study","volume":"84","author":"Foroughi","year":"2022","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.tem.2022.06.005_bb0060","doi-asserted-by":"crossref","first-page":"208","DOI":"10.5507\/bp.2014.060","article-title":"The common pathophysiology underlying the metabolic syndrome, schizophrenia and depression. A review","volume":"159","author":"Kucerova","year":"2015","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub."},{"key":"10.1016\/j.tem.2022.06.005_bb0065","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3389\/fnins.2017.00741","article-title":"The complex relationship between antipsychotic-induced weight gain and therapeutic benefits: a systematic review and implications for treatment","volume":"11","author":"Raben","year":"2018","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.tem.2022.06.005_bb0070","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3390\/ph14030238","article-title":"Atypical antipsychotics and metabolic syndrome: from molecular mechanisms to clinical differences","volume":"14","author":"Carli","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.tem.2022.06.005_bb0075","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2021.07.009","article-title":"Mortality and non-use of antipsychotic drugs after acute admission in schizophrenia: a prospective total-cohort study","volume":"235","author":"Str\u00f8mme","year":"2021","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.tem.2022.06.005_bb0080","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","author":"American Diabetes Association","year":"2004","journal-title":"Diab. Care"},{"key":"10.1016\/j.tem.2022.06.005_bb0085","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s40265-020-01393-x","article-title":"Pharmacological management of glucose dysregulation in patients treated with second-generation antipsychotics","volume":"80","author":"Cernea","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.tem.2022.06.005_bb0090","first-page":"CD013006","article-title":"Interventions for the management of obesity in people with bipolar disorder","volume":"7","author":"Tully","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.tem.2022.06.005_bb0095","doi-asserted-by":"crossref","DOI":"10.1192\/j.eurpsy.2020.115","article-title":"Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: a Delphi expert consensus study","volume":"64","author":"Galderisi","year":"2021","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.tem.2022.06.005_bb0100","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/acps.13266","article-title":"How and when to treat the most common adverse effects of antipsychotics: expert review from research to clinical practice","volume":"143","author":"Stahl","year":"2021","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.tem.2022.06.005_bb0105","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ebmental-2021-300291","article-title":"Metformin in the management of antipsychotic-induced weight gain in adults with psychosis: development of the first evidence-based guideline using GRADE methodology","volume":"25","author":"Fitzgerald","year":"2022","journal-title":"Evid. Based Ment. Health"},{"key":"10.1016\/j.tem.2022.06.005_bb0110","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2337\/cd22-as01","article-title":"Standards of medical care in diabetes \u2013 2022 abridged for primary care providers","volume":"40","author":"American Diabetes Association","year":"2022","journal-title":"Clin. Diab."},{"key":"10.1016\/j.tem.2022.06.005_bb0115","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1161\/ATVBAHA.119.311904","article-title":"How do SGLT2 (sodium-glucose cotransporter 2) inhibitors and GLP-1 (glucagon-like peptide-1) receptor agonists reduce cardiovascular outcomes? Completed and ongoing mechanistic trials","volume":"40","author":"Lee","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.tem.2022.06.005_bb0120","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1080\/13543784.2021.1951702","article-title":"Treating cognitive impairment in schizophrenia with GLP-1RAs: an overview of their therapeutic potential","volume":"30","author":"Flintoff","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.tem.2022.06.005_bb0125","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.eurpsy.2018.07.004","volume":"54","author":"Stubbs","year":"2018","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.tem.2022.06.005_bb0130","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/wps.20614","article-title":"The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials","volume":"18","author":"Vancampfort","year":"2019","journal-title":"World Psychiatry"},{"key":"10.1016\/j.tem.2022.06.005_bb0135","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jad.2021.08.023","article-title":"Clozapine induces metformin-resistant prediabetes\/diabetes that is associated with poor clinical efficacy in patients with early treatment-resistant schizophrenia","volume":"295","author":"Zhuo","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.tem.2022.06.005_bb0140","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1093\/schbul\/sbaa191","article-title":"Does switching antipsychotics ameliorate weight gain in patients with severe mental illness? A systematic review and meta-analysis","volume":"47","author":"Siskind","year":"2021","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.tem.2022.06.005_bb0145","doi-asserted-by":"crossref","DOI":"10.1177\/20451253211045248","article-title":"CoMET: a randomised controlled trial of co-commencement of metformin versus placebo as an adjunctive treatment to attenuate weight gain in patients with schizophrenia newly commenced on clozapine","volume":"11","author":"Siskind","year":"2021","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.tem.2022.06.005_bb0150","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/0269881107077815","article-title":"Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents","volume":"22","author":"Ojala","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.tem.2022.06.005_bb0155","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/YIC.0000000000000014","article-title":"Pharmacological treatment of antipsychotic-induced dyslipidemia and hypertension","volume":"29","author":"Tse","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.tem.2022.06.005_bb0160","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3389\/fendo.2019.00260","article-title":"From the incretin concept and the discovery of GLP-1 to today\u2019s diabetes therapy","volume":"10","author":"Holst","year":"2019","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.tem.2022.06.005_bb0165","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3389\/fendo.2018.00672","article-title":"Pleiotropic effects of GLP-1 and analogs on cell signaling, metabolism, and function","volume":"9","author":"Rowlands","year":"2018","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.tem.2022.06.005_bb0170","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1210\/endrev\/bnaa032","article-title":"Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation","volume":"42","author":"McLean","year":"2021","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.tem.2022.06.005_bb0175","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.14496","article-title":"The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update","volume":"23","author":"Nauck","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.tem.2022.06.005_bb0180","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3803\/EnM.2020.934","article-title":"Efficacy and safety of the new appetite suppressant, liraglutide: a meta-analysis of randomized controlled trials","volume":"36","author":"Moon","year":"2021","journal-title":"Endocrinol. Metab."},{"key":"10.1016\/j.tem.2022.06.005_bb0185","doi-asserted-by":"crossref","DOI":"10.1177\/2042018821997320","article-title":"GLP-1 receptor agonists: an updated review of head-to-head clinical studies","volume":"12","author":"Trujillo","year":"2021","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2022.06.005_bb0190","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1007\/s12020-021-02945-1","article-title":"Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis","volume":"75","author":"Zhong","year":"2022","journal-title":"Endocrine"},{"key":"10.1016\/j.tem.2022.06.005_bb0195","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bph.15682","article-title":"Glucagon-like peptide-1 (GLP-1) signalling in the brain: from neural circuits and metabolism to therapeutics","volume":"179","author":"Kabahizi","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tem.2022.06.005_bb0200","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/joim.13433","article-title":"Glucagon-like peptide-1 (GLP-1) \u2013 are its roles as endogenous hormone and therapeutic wizard congruent?","volume":"291","author":"Holst","year":"2022","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.tem.2022.06.005_bb0205","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.amjcard.2021.05.043","article-title":"Usefulness of glucagon-like peptide-1 receptor agonists to reduce adverse cardiovascular disease events in patients with type 2 diabetes mellitus","volume":"154","author":"Grewal","year":"2021","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.tem.2022.06.005_bb0210","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/1815178","article-title":"The impact of incretin-based medications on lipid metabolism","volume":"2021","author":"Yaribeygi","year":"2021","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.tem.2022.06.005_bb0215","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1016\/j.celrep.2019.05.055","article-title":"Distinct neural sites of GLP-1R expression mediate physiological versus pharmacological control of incretin action","volume":"27","author":"Varin","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.tem.2022.06.005_bb0220","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/NMD.0b013e318221403d","article-title":"Implications of weight-based stigma and self-bias on quality of life among individuals with schizophrenia","volume":"199","author":"Barber","year":"2011","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.tem.2022.06.005_bb0225","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/jamapsychiatry.2017.1220","article-title":"Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial","volume":"74","author":"Larsen","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.tem.2022.06.005_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2021.113830","article-title":"Effect of liraglutide 3.0 mg treatment on weight reduction in obese antipsychotic-treated patients","volume":"299","author":"Lee","year":"2021","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.tem.2022.06.005_bb0235","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/dom.14334","article-title":"The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: results of a pilot randomised double-blind placebo-controlled trial","volume":"23","author":"Whicher","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.tem.2022.06.005_bb0240","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/dom.12795","article-title":"Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial","volume":"19","author":"Ish\u00f8y","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.tem.2022.06.005_bb0245","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1111\/dom.13167","article-title":"Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: a randomized controlled trial (CODEX)","volume":"20","author":"Siskind","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.tem.2022.06.005_bb0250","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/dom.13522","article-title":"Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: a systematic review and individual participant data meta-analysis","volume":"21","author":"Siskind","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.tem.2022.06.005_bb0255","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jpsychires.2020.02.015","article-title":"Metabolic measures 12 months after a randomised controlled trial of treatment of clozapine associated obesity and diabetes with exenatide (CODEX)","volume":"124","author":"Siskind","year":"2020","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.tem.2022.06.005_bb0260","first-page":"19m02504","article-title":"Glucagon-like peptide analogs are superior for diabetes and weight control in patients on antipsychotic medications: a retrospective cohort study","volume":"22","author":"Perlis","year":"2020","journal-title":"Prim. Care Companion CNS Disord."},{"key":"10.1016\/j.tem.2022.06.005_bb0265","article-title":"Understanding the effects of antipsychotics on appetite control","volume":"8","author":"Mukherjee","year":"2021","journal-title":"Front. Nutr."},{"key":"10.1016\/j.tem.2022.06.005_bb0270","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/jamapsychiatry.2017.3053","article-title":"Liraglutide for the treatment of antipsychotic drug-induced weight gain","volume":"74","author":"Deutch","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.tem.2022.06.005_bb0275","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.schres.2008.05.011","article-title":"The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance","volume":"103","author":"Lykkegaard","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.tem.2022.06.005_bb0280","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/0269881118756061","article-title":"Liraglutide prevents metabolic side-effects and improves recognition and working memory during antipsychotic treatment in rats","volume":"32","author":"Babic","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.tem.2022.06.005_bb0285","doi-asserted-by":"crossref","first-page":"E1101","DOI":"10.1152\/ajpendo.00309.2020","article-title":"GLP1 receptor agonism protects against acute olanzapine-induced hyperglycemia","volume":"319","author":"Medak","year":"2020","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2022.06.005_bb0290","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11011-014-9591-7","article-title":"GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats","volume":"30","author":"Sharma","year":"2015","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.tem.2022.06.005_bb0295","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4088\/JCP.14074su1c.02","article-title":"Impact of cognitive and social cognitive impairment on functional outcomes in patients with schizophrenia","volume":"77","author":"Green","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.tem.2022.06.005_bb0300","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.717824","article-title":"Metabolic syndrome impairs executive function in bipolar disorder","volume":"15","author":"Dalkner","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.tem.2022.06.005_bb0305","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/schbul\/sbab064","article-title":"Obesity as a risk factor for accelerated brain ageing in first-episode psychosis \u2013 a longitudinal study","volume":"47","author":"McWhinney","year":"2021","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.tem.2022.06.005_bb0310","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/schbul\/sbab002","article-title":"A network of psychopathological, cognitive, and motor symptoms in schizophrenia spectrum disorders","volume":"47","author":"Moura","year":"2021","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.tem.2022.06.005_bb0315","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/wps.20522","article-title":"Antipsychotic drugs: challenges and future directions","volume":"17","author":"Howes","year":"2018","journal-title":"World Psychiatry"},{"key":"10.1016\/j.tem.2022.06.005_bb0320","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/schbul\/sbab010","article-title":"Simvastatin augmentation for patients with early-phase schizophrenia-spectrum disorders: a double-blind, randomized placebo-controlled trial","volume":"47","author":"Sommer","year":"2021","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.tem.2022.06.005_bb0325","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1080\/02699052.2019.1587000","article-title":"GLP-1\u2019s role in neuroprotection: a systematic review","volume":"33","author":"Erbil","year":"2019","journal-title":"Brain Inj."},{"key":"10.1016\/j.tem.2022.06.005_bb0330","first-page":"1257","article-title":"Repurposing of anti-diabetic agents as a new opportunity to alleviate cognitive impairment in neurodegenerative and neuropsychiatric disorders","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tem.2022.06.005_bb0335","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/s41366-020-0535-5","article-title":"Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study","volume":"44","author":"Vadini","year":"2020","journal-title":"Int. J. Obes. (Lond.)"},{"key":"10.1016\/j.tem.2022.06.005_bb0340","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jad.2016.09.056","article-title":"Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: a pilot, open-label study","volume":"207","author":"Mansur","year":"2017","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.tem.2022.06.005_bb0345","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/acps.12711","article-title":"No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia","volume":"136","author":"Ish\u00f8y","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.tem.2022.06.005_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118645","article-title":"GLP-1 mimetics and cognition","volume":"264","author":"Yaribeygi","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.tem.2022.06.005_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.05.032","article-title":"Brain insulin action: implications for the treatment of schizophrenia","volume":"168","author":"Agarwal","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.tem.2022.06.005_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.05.010","article-title":"Brain insulin action in schizophrenia: something borrowed and something new","volume":"163","author":"Agarwal","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.tem.2022.06.005_bb0365","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/mp.2008.40","article-title":"Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway","volume":"13","author":"Girgis","year":"2008","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.tem.2022.06.005_bb0370","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.schres.2008.11.025","article-title":"Common effect of antipsychotics on the biosynthesis and regulation of fatty acids and cholesterol supports a key role of lipid homeostasis in schizophrenia","volume":"108","author":"Polymeropoulos","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.tem.2022.06.005_bb0375","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3389\/fpsyt.2020.00480","article-title":"Assessment of appetite-regulating hormones provides further evidence of altered adipoinsular axis in early psychosis","volume":"11","author":"Lis","year":"2020","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.tem.2022.06.005_bb0380","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.schres.2017.03.031","article-title":"Lipid profile disturbances in antipsychotic-naive patients with first-episode non-affective psychosis: a systematic review and meta-analysis","volume":"190","author":"Misiak","year":"2017","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.tem.2022.06.005_bb0385","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.schres.2014.09.038","article-title":"Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial","volume":"160","author":"Ramsey","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.tem.2022.06.005_bb0390","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3389\/fpsyt.2018.00784","article-title":"Feasibility, adherence and efficacy of liraglutide treatment in a sample of individuals with mood disorders and obesity","volume":"9","author":"Cuomo","year":"2018","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.tem.2022.06.005_bb0395","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12888-021-03666-5","article-title":"Liraglutide and the management of overweight and obesity in people with severe mental illness: qualitative sub-study","volume":"22","author":"Barnard-Kelly","year":"2022","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.tem.2022.06.005_bb0400","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s13679-020-00422-w","article-title":"Long-term efficacy and safety of anti-obesity treatment: where do we stand?","volume":"10","author":"Tak","year":"2021","journal-title":"Curr. Obes. Rep."},{"key":"10.1016\/j.tem.2022.06.005_bb0405","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/jamapsychiatry.2017.2702","article-title":"Liraglutide for the treatment of antipsychotic drug-induced weight gain \u2013 reply","volume":"74","author":"Fink-Jensen","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.tem.2022.06.005_bb0410","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1007\/s43440-021-00274-8","article-title":"Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression","volume":"73","author":"Detka","year":"2021","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.tem.2022.06.005_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107704","article-title":"Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology","volume":"172","author":"Kaar","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.tem.2022.06.005_bb0420","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.mp.4002066","article-title":"Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles","volume":"13","author":"Nasrallah","year":"2008","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.tem.2022.06.005_bb0425","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.3390\/cells8111336","article-title":"Second-generation antipsychotics and dysregulation of glucose metabolism: beyond weight gain","volume":"8","author":"Grajales","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.tem.2022.06.005_bb0430","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.161","article-title":"A potential mechanism underlying atypical antipsychotics-induced lipid disturbances","volume":"5","author":"Cai","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.tem.2022.06.005_bb0435","doi-asserted-by":"crossref","first-page":"158534","DOI":"10.1016\/j.bbalip.2019.158534","article-title":"Adipose tissue as a target for second-generation (atypical) antipsychotics: a molecular view","volume":"1865","author":"Ferreira","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.tem.2022.06.005_bb0440","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1017\/S1461145713000862","article-title":"Olanzapine depot formulation in rat: a step forward in modelling antipsychotic-induced metabolic adverse effects","volume":"17","author":"Skrede","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.tem.2022.06.005_bb0445","article-title":"Interacting effects of the MAM model of schizophrenia and antipsychotic treatment: untargeted proteomics approach in adipose tissue","volume":"2021","author":"Kucera","year":"2020","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.tem.2022.06.005_bb0450","doi-asserted-by":"crossref","first-page":"e899","DOI":"10.4088\/JCP.13m08820","article-title":"Glucometabolic hormones and cardiovascular risk markers in antipsychotic-treated patients","volume":"75","author":"Ebdrup","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.tem.2022.06.005_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2021.114227","article-title":"Glucagon-like peptide-1 serum levels are associated with weight gain in patients treated with clozapine","volume":"306","author":"Klemettil\u00e4","year":"2021","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.tem.2022.06.005_bb0460","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1530\/EJE-09-0433","article-title":"Short-term treatment with olanzapine does not modulate gut hormone secretion: olanzapine disintegrating versus standard tablets","volume":"162","author":"Vidarsdottir","year":"2010","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.tem.2022.06.005_bb0465","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.2337\/db13-0430","article-title":"Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease","volume":"62","author":"Teff","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.tem.2022.06.005_bb0470","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.schres.2009.07.011","article-title":"Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour","volume":"115","author":"Smith","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.tem.2022.06.005_bb0475","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.psyneuen.2016.07.218","article-title":"Olanzapine-depot administration induces time-dependent changes in adipose tissue endocrine function in rats","volume":"73","author":"Horska","year":"2016","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.tem.2022.06.005_bb0480","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1177\/0269881120981377","article-title":"Effect of liraglutide on neural and peripheral markers of metabolic function during antipsychotic treatment in rats","volume":"35","author":"Babic","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.tem.2022.06.005_bb0485","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.neuropharm.2017.06.003","article-title":"Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats","volume":"123","author":"Horska","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.tem.2022.06.005_bb0490","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1177\/0269881117691466","article-title":"Depot risperidone-induced adverse metabolic alterations in female rats","volume":"31","author":"Horska","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.tem.2022.06.005_bb0495","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/s41401-021-00680-x","article-title":"Brexpiprazole caused glycolipid metabolic disorder by inhibiting GLP1\/GLP1R signaling in rats","volume":"42","author":"Li","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.tem.2022.06.005_bb0500","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/acps.12982","article-title":"One-year follow-up on liraglutide treatment for prediabetes and overweight\/obesity in clozapine- or olanzapine-treated patients","volume":"139","author":"Svensson","year":"2019","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.tem.2022.06.005_bb2005","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1080\/13696998.2019.1685818","article-title":"Association of antipsychotic treatment switching in patients with schizophrenia, bipolar, and major depressive disorders","volume":"23","author":"Ayyagari","year":"2020","journal-title":"J. Med. Econ."}],"container-title":["Trends in Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043276022001229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043276022001229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T20:43:29Z","timestamp":1760906609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043276022001229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":101,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1043276022001229"],"URL":"https:\/\/doi.org\/10.1016\/j.tem.2022.06.005","relation":{},"ISSN":["1043-2760"],"issn-type":[{"value":"1043-2760","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 agonists: superior for mind and body in antipsychotic-treated patients?","name":"articletitle","label":"Article Title"},{"value":"Trends in Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tem.2022.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}